Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Fasinumab (Primary) ; Celecoxib; Diclofenac
- Indications Pain
- Focus Registrational; Therapeutic Use
- Acronyms FACT OA2
- Sponsors Regeneron Pharmaceuticals
- 04 Sep 2018 Planned number of patients changed from 2700 to 1620.
- 10 Jul 2018 This trial has been discontinued in Denmark.
- 12 Mar 2018 Planned End Date changed from 5 Jun 2020 to 15 Jun 2020.